VTX:NOVN - Novartis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolume11.21 million shsAverage Volume5.98 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. Read More… Industry, Sector and Symbol Stock Exchange VTX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolVTX:NOVN Previous Symbol CUSIPN/A CIKN/A Webhttp://www.novartis.com/ Phone+41-61-3241111Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees47 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive NOVN News and Ratings via Email Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter. NOVN Rates by TradingView Novartis (VTX:NOVN) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the VTX under the ticker symbol "NOVN." What price target have analysts set for NOVN? 12 brokerages have issued twelve-month price objectives for Novartis' shares. Their forecasts range from CHF 85 to CHF 113. On average, they anticipate Novartis' stock price to reach CHF 95.75 in the next year. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? Media stories about NOVN stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Novartis. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM) and China Longyi Group Int'l (CGYG). What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Novartis (NVS), Iamgold (IAG), General Motors (GM), DigitalGlobe (DGI), NovaGold Resources (NG), AstraZeneca (AZN), Cyberark Software (CYBR), Micron Technology (MU), Alibaba Group (BABA) and Walt Disney (DIS). Who are Novartis' key executives? Novartis' management team includes the folowing people: Mr. G. Kelly Martin, CEO & Director (Age 60)Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)Dr. Carri Geer, Sr. VP & CTO What is Novartis' official website? The official website for Novartis is http://www.novartis.com/. How can I contact Novartis? Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111. MarketBeat Community Rating for Novartis (VTX NOVN)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 337 (Vote Underperform)Total Votes: 575MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What does the Producer Price Index (PPI) tell investors?
